Abstract Library

#4589 Clinical efficacy of RLT to assess OS and PFS using 177Lu DOTATATE, 90Y DOTATATE, and a mixture of both in patients with advanced, unresectable, progressive rectal NET – A retrospective analysis

Introduction: Retrospective, single-arm, open-label, case series study evaluating the efficacy of different types of radioligand therapy (RLT): 177Lu, 90Y DOTATATE, or mix of both used in advanced, unresectable progressive rectal NETG1/G2.

Conference:

Presenting Author: Ćwikła J

Authors: Kolasińska-Ćwikla A, Sankowski A, Pałucki J, Sekelcka N, Ćwikła J,

Keywords: Rectal Neuroendocrine Tumour, SST Receptor, Radioligand Therapy (RLT),

#3833 Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (NET) treated initially with Lanreotide AG and methods of further treatment approaches after progression real-world data

Introduction: .

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślicka A, Bednarczuk T, Osowiecka K, Słoniewska A,

Keywords: advanced NET, non-resectable pancreatic neuroendocrine tumor, Lanreotide therapy, real word data set,

#3819 Dosimetry evaluation in 177Lu-labeled somatostatin receptor analogue therapy

Introduction: Dosimetry reporting in patients receiving PRRT is fundamental to ensure the safety and efficacy of treatment.

Conference:

Presenting Author:

Authors: Cichoński A, Kempińska-Wróbel M, Kolasińska-Ćwikła A, Zrajkowska A, Szarowicz A,

Keywords: radionuclide therapy, dosimetry, lutetium,

#3039 Evaluation of Overall Survival (OS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)

Introduction: In many cases, the cause of death in patients with carcinoid syndrome (CS) is carcinoid heart disease (CHD) which is most often diagnosed in patients with SI-NEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ćwikła J

Authors: Konsek-Komorowska S, Pęczkowska M, Kolasińska-Ćwikła A, Cichocki A, Roszkowska-Purska K,

Keywords: Neuroendocrine Neoplasms of the Small Intestine, SI-NENs, carcinoid syndrome, carcinoid heart disease, Overall Survival,

#2098 Systemic Anti-Cancer Therapies in Neuroendocrine Tumor Patients Impair Nutritional Status

Introduction: Malnutrition is a clinical relevant problem in NEN-patients (pts) independently influencing overall prognosis, particularly in pts undergoing chemotherapy (CTx). A poor nutritional status (NS) in pts of all WHO-grades was associated with a significantly shorter long-term outcome

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pevny S, Maasberg S, Karber M, Knappe-Drzikova B, Weylandt K,

Keywords: nutritional status, malnutrition, chemotherapy, somatostatin analogues, everolimus, NETG1/G2, survival,